General Information of Drug (ID: DMNRMTX)

Drug Name
13,14-dihydro-16-m-chlorophenoxy-w-tetranor-PGF1alpha Drug Info
Synonyms
CHEMBL36041; 7-[(1R,2R,3R,5S)-2-[(3R)-4-(3-chlorophenoxy)-3-hydroxybutyl]-3,5-dihydroxycyclopentyl]heptanoic acid; AC1NSKAB; GTPL1955; 13,14-dihydro-16-m-chlorophenoxy-w-tetranor-PGF1alpha; 13,14-Dihydro-16-m-Chlorophenoxy-Omega-Tetranor PGF-1alpha; BDBM50085911; 7-{2-[4-(3-Chloro-phenoxy)-3-hydroxy-butyl]-3,5-dihydroxy-cyclopentyl}-heptanoic acid; 7-[(1R)-2beta-[(3R)-3-Hydroxy-4-(3-chlorophenoxy)butyl]-3alpha,5alpha-dihydroxycyclopentane-1alpha-yl]heptanoic acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5311240
TTD Drug ID
DMNRMTX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [3]
Latanoprost DMI5OXG Ocular hypertension 9C61.01 Approved [4]
BOL-303259-X DM2EXC5 Open-angle glaucoma 9C61 Approved [5]
Tafluprost DMFC41K Glaucoma/ocular hypertension 9C61 Approved [6]
Carboprost Tromethamine DMS3508 Abortion JA00 Approved [7]
Travoprost DM20K91 Ocular hypertension 9C61.01 Approved [8]
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [9]
PGF2ALPHA-IE DM5DAP3 Glaucoma/ocular hypertension 9C61 Phase 3 [10]
ONO-9054 DM5O6GC Glaucoma/ocular hypertension 9C61 Phase 2 [11]
PDC-41 DM74YO8 Dysmenorrhea GA34.3 Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin F2-alpha receptor (PTGFR) TTT2ZAR PF2R_HUMAN Agonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1955).
2 Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor. J Med Chem. 2000 Mar 9;43(5):945-52.
3 Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
4 PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res. 2009 Jan;15(1):62-70.
5 Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8.
9 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
10 Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994 Oct;59(4):401-7.
11 IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
12 THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol. 2002 Dec;26(6):389-97.